Teva Pharma Industries Ltd ADR
Yahoo Finance • 3 days ago
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks
Key Points Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarter all in the sector. Biotec... Full story
Yahoo Finance • 7 days ago
Nanotechnology Drug Delivery Market Projected to Reach USD 200.77 Billion by 2032, Owing to Prevalence of Chronic Diseases & Advances in Nanomedicine – SNS Insider
Austin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Nanotechnology Drug Delivery Market Size & Growth Analysis According to a SNS Insider, the Nanotechnology Drug Delivery Market size was valued at USD 96.39 billion in 2024 and is projected to re... Full story
Yahoo Finance • 7 days ago
Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva®
Suite aux avis favorables rendus par le Comité des médicaments à usage humain (CMUH), la Commission européenne a accordé des autorisations de mise en marché visant les biosimilaires PONLIMSI et DEGEVMA de Teva, élargissant ainsi l’accès à... Full story
Yahoo Finance • 7 days ago
Teva erhält Zulassung der Europäischen Kommission für PONLIMSI® (Denosumab), ein Biosimilar zu Prolia®, und DEGEVMA® (Denosumab), ein Biosimilar zu Xgeva®
Aufgrund der positiven Stellungnahmen des Ausschusses für Humanarzneimittel (CHMP) hat die Europäische Kommission die Zulassungen für die Biosimilars PONLIMSI und DEGEVMA von Teva erteilt und damit den Zugang zu wichtigen Behandlungen für... Full story
Yahoo Finance • 8 days ago
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA expanding access to important bone healt... Full story
Yahoo Finance • 8 days ago
Why Analysts See Teva’s Story Shifting With New Approvals and Rising Price Targets
Teva Pharmaceutical Industries stock has drawn renewed attention after consensus analyst price targets edged higher, rising from $27.45 to $27.90 per share. This subtle adjustment reflects a blend of cautious optimism, influenced by both r... Full story
Yahoo Finance • 9 days ago
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.
Neilson Barnard / Getty Images Entertainment via Getty Images Quick Read Druckenmiller produced 30% average annual returns with no losing years at Duquesne from 1981 to 2010. Natera (NTRA) revenue rose 35% year-over-year in Q3 2025 and b... Full story
Yahoo Finance • 12 days ago
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management will present at three... Full story
Yahoo Finance • 15 days ago
Japan Contraceptives Drugs Analysis Report 2025: A $1+ Billion Market by 2030 - Technological Advancements in Drug Delivery and Digital Integration Further Propel Expansion
Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Japan Contraceptives Drugs Market by Region, Competition, Forecast & Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's offering. The Japan Contraceptives Drugs... Full story
Yahoo Finance • 19 days ago
Cold Agglutinin Disease (CAD) Market Analysis, Business Prospects, Case Studies and Competitive Intelligence 2025-2035
Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Cold Agglutinin Disease Market - A Global and Regional Analysis: Focus on Drug Class, Dosage Form, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's... Full story
Yahoo Finance • 19 days ago
Social Anxiety Disorder (SAD/Social Phobia) Global Clinical Trials Market Review 2025 by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Social Anxiety Disorder (SAD/Social Phobia) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides top line data... Full story
Yahoo Finance • 26 days ago
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XRMost (85%) participants taking AUSTED... Full story
Yahoo Finance • 27 days ago
Ventricular Hypertrophy Industry Growth Report Report 2025-2035 - Advancements in Telemedicine Presenting New Avenues for Remote Patient Management
Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Ventricular Hypertrophy Market - A Global and Regional Analysis: Focus on Route of Administration and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's o... Full story
Yahoo Finance • 27 days ago
S&P 500 Futures Dip as Rate and Debt Worries Mount
The Morning Bull - US Market Morning Update Thursday, Nov, 6 2025 US stock futures are pointing lower ahead of the open, as investors react to news that US household debt has climbed to a fresh all-time high and the 10-year Treasury yield... Full story
Yahoo Finance • 28 days ago
Apple's reported Google deal, Teva & Axon post-earnings moves
Market Domination host Josh Lipton examines some of Wednesday's trending tickers. Apple (AAPL) is reportedly nearing a deal with Alphabet (GOOG, GOOGL) to overhaul Siri, according to Bloomberg. Teva (TEVA) stock rose after the company re... Full story
Yahoo Finance • 28 days ago
Teva gains after Q3 beat and guidance hike
[Building of Teva Canada Markham manufacturing facility.] JHVEPhoto/iStock Editorial via Getty Images Shares of Teva Pharmaceutical (TEVA [https://seekingalpha.com/symbol/TEVA]) jumped ~11% in the premarket on Wednesday after the generic... Full story
Yahoo Finance • 28 days ago
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Exclu... Full story
Yahoo Finance • 28 days ago
Teva Pharmaceutical Industries Q3 25 Earnings Conference Call At 8:00 AM ET
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) will host a conference call at 8:00 AM ET on November 5, 2025, to discuss Q3 25 earnings results. To access the live webcast, log on to https://ir.tevapharm.com/Events-and-Presenta... Full story
Yahoo Finance • last month
Trump Administration Eases Approval Process for Biosimilar Drugs
The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive for drugmakers to develop biosimilar medicines, the copycat versions of off-patent biologic drugs. Under the new dra... Full story
Yahoo Finance • last month
United States Alzheimer Drugs Research Report 2025: Market to Reach $4.47 Billion by 2033 - 7.78% CAGR Fueled by Drug Innovation and Early Diagnosis
Dublin, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The "United States Alzheimer Drugs Market to Reach US$ 4.47 Billion by 2033 - 7.78% CAGR Fueled by Drug Innovation and Early Diagnosis" report has been added to ResearchAndMarkets.com's offering... Full story
